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Background: Prostate stem cell antigen (PSCA) has been implicated in the pathogenesis of several solid
tumours, either due to changes in protein expression, or through association with the rs2294008 polymorphism in
the PSCA gene. To our knowledge, the role of PSCA in the development of colorectal neoplasia has not been
explored. We performed a genotyping study to assess for associations between the rs2294008 polymorphism
and risk of adenomatous polyps and colorectal cancer. DNA samples were available from 388 individuals with
colorectal neoplasia and 496 controls, all of whom had undergone screening colonoscopy. In addition,
we performed immunohistochemical staining for PSCA in colonic tissue representing all stages of the
adenoma-carcinoma sequence.
Results: No genotypic associations were found between the rs2294008 polymorphism and the risk of colorectal
adenomata or cancer. Immunohistochemical staining did not reveal any alteration in PSCA expression
accompanying the adenoma-carcinoma sequence.
Conclusion: From these data it seems unlikely that PSCA has a role in the initiation or progression of
colorectal neoplasia.
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Prostate stem cell antigen was first described as a mar-
ker overexpressed in prostate cancer [1], and was subse-
quently found to be associated with increasing disease
stage and other adverse prognostic features [2,3]. Over-
expression of PSCA, either at mRNA or protein level,
has also been described in several other human solid
cancers including those of bladder, endometrium, kid-
ney, pancreas, ovary, central nervous system, and lung* Correspondence: e.el-omar@abdn.ac.uk
†Equal contributors
1Gastrointestinal Research Group, Institute of Medical Sciences, University of
Aberdeen, Aberdeen AB25 2ZD, Scotland
3Room 6.20, Institute of Medical Sciences, University of Aberdeen, Aberdeen
AB25 2ZD, Scotland
Full list of author information is available at the end of the article
© 2012 Smith et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the or[4-10]. Alterations in PSCA expression have been impli-
cated in upper gastrointestinal carcinogenesis, with loss
of PSCA expression reported in gastric, oesophageal,
and gallbladder cancer, and intestinal metaplasia, a gas-
tric cancer precursor lesion [11-13]. The role of PSCA
in tumourigenesis cannot be conveniently assigned to
that of tumour suppressor gene or oncogene, but rather
appears to be context or tissue specific [14]. The
rs2294008 polymorphism denotes a C>T transition in
exon 1 of the gene, at the presumed transcription initi-
ation site. The polymorphism appears, from in vitro
data, to be functional, and the risk allele (T) has been
shown to be associated with gastric cancer risk in Asians
and white individuals [11,15]. Given that PSCA expres-
sion and the rs2294008 polymorphism have beentd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Association between the rs2294008 polymorphism and risk of colorectal neoplasia (cancer and adenomata)
Genotype model Neoplasia cases (n) Controls (n) *OR 95% CI
Per-Genotype
C/C 140 172 Reference
C/T 181 245 0.93 0.69–1.25
T/T 67 76 1.09 0.73–1.63
Dominant
C/C 140 172 Reference
C/T + T/T 248 321 0.97 0.73–1.28
Recessive
C/C + C/T 321 417 Reference
T/T 67 76 1.14 0.79–1.64
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tinal tract, we were interested in whether PSCA was
relevant to colorectal cancer, the commonest gastro-
intestinal malignancy, and a leading global cause of
cancer-related death [16]. We therefore performed a
genotyping study involving the screened population of
North East Scotland, and an immunohistochemical
study using neoplastic colonic tissue covering all stages
of the adenoma-carcinoma sequence.
Results
Genotyping
For the rs2294008 polymorphism (C>T), the frequency
of alleles in the control population (no neoplasia,
n = 493) was in Hardy-Weinberg Equilibrium, with a
non-significant chi-squared value (0.463).
In an initial comparison, cases were defined as partici-
pants with adenomatous polyps or cancer, and controls
were defined as individuals with no colonoscopic evi-
dence of neoplasia. In logistic regression analyses, none
of the genotype models yielded significant odds ratios
(OR), suggesting that no association exists between theTable 2 Association between the rs2294008 polymorphism an







C/T + T/T 52
Recessive
C/C + C/T 64
T/T 13
*OR adjusted for age and sex. Odds ratios and confidence intervals are given for pers2294008 polymorphism and risk of colorectal neoplasia
(Table 1). In a second analysis, cases were defined as indi-
viduals harbouring invasive adenocarcinoma only, and the
remainder of subjects (both those with and without
adenomata) were used as the control population (Table 2).
Again, no significant associations existed between the
rs2294008 polymorphism and cancer risk.Immunohistochemistry
All slides were reviewed by a consultant pathologist
(GM). PSCA expression in normal mucosa was exam-
ined by assessing non-adenomatous mucosa contained
within the polypectomy specimens [17,18]. In all colonic
tissue examined, neuroendocrine cells stained intensely
for PSCA expression, as anticipated from previous studies
[1] (Figure 1A, arrow). In colonocytes, however, staining
for PSCA was weak or absent. There was no alteration in
the topographic distribution or intensity of PSCA staining
between normal mucosa (Figure 1B), adenomatous mu-
cosa with low or high grade epithelial dysplasia
(Figure 1C), and invasive carcinoma (Figure 1D).d risk of colorectal cancer








r-genotype, dominant, and recessive models.
Figure 1 Photomicrographs of colonic tissue immunohistochemically stained for PSCA. Intense staining can be seen in a crypt
neuroendocrine cell (1A, arrow). Colonocytes show little or no staining across all stages of the adenoma-carcinoma sequence. No changes in
intensity or topographic distribution of PSCA expression were observed between normal mucosa (1B), adenomatous tissue displaying low grade
epithelial dysplasia (1C), and invasive carcinoma (1D).
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Here, we report the first study examining the role of the
rs2294008 polymorphism in the PSCA gene in colorectal
neoplasia. In a case-control study, derived from subjects
undergoing colonoscopy for CRC screening, we found no
statistically significant association between the rs2294008
polymorphism and the risk of either adenomatous polyps
or CRC. Immunohistochemical staining for PSCA protein
expression in normal colonic epithelium, adenomatous
epithelium displaying low and high grade epithelial dyspla-
sia, and invasive adenocarcinoma, revealed no apparent
differences in the level of PSCA expression. Potential
weaknesses of this study include the relatively small total
study size. We cannot therefore exclude that an associ-
ation between rs2294008 and colorectal neoplasia exists,
but that we failed to detect it due to limited statistical
power. A further caveat is that loss of PSCA expression by
colonic epithelial cells may not be detectable by immuno-
histochemical analysis when normal levels of staining were
weak or absent. Several studies have, however, successfully
demonstrated differential PSCA protein expression in
tumour vs. normal tissue using IHC [2,3,5]. Alternative
techniques such as in-situ hybridization, or qPCR, could
be employed to assess transcriptional changes in PSCA in
colon tissue. Although our study has generated negative
findings, it is nonetheless interesting that PSCA does notappear to have a role in the initiation or progression of
colorectal neoplasia. This is in contrast to a variety of
other solid cancers, including several gastrointestinal tract
cancers, which display altered levels of PSCA expression
[4-13]. PSCA expression appears to have potential as a
biomarker in prostate cancer, and the rs2294008 poly-
morphism may influence survival in diffuse type gastric
cancer [19-22].
The normal function of PSCA in vivo remains obscure
and its role in carcinogenesis appears complex. Both
tumour promotion and suppression roles have been pos-
tulated given that loss or up regulation of PSCA protein
expression has been observed in different types of
human solid tumours [4-13]. Furthermore, in a gastric
cancer cell line, overexpression of PSCA was shown to
reduce cell proliferation [11]; in contrast, knock down of
PSCA in a bladder cancer cell line was associated with
induction of an inflammatory gene expression set and
diminished cell growth [23]. Thus, the effects of PSCA
appear to depend on the cellular or tissue context [14].
PSCA belongs to the lymphocyte antigen 6 (Ly-6) super-
family of glycosylphosphatidylinositol (GPI)-anchored cell
surface proteins. Other members of the Ly-6 family are
involved in immune regulation and cellular differentiation
[24]. The related molecule, SLURP-1, modulates α7
subunit-containing nicotinic acetylcholine receptor (α7-
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cated in epidermal immune homeostasis [25,26]. In a
mouse model of ciliary ganglion development, PSCA has
been shown to rescue a neuronal subpopulation from
cell death through a α7-nAChR-dependent mechanism
[27]. We have previously hypothesised that PSCA may
interact with α7-nAChR in humans, and serve as an im-
mune or inflammatory modulator in epithelial tissues. It
is of note that the GI cancers thus far associated with
PSCA all arise in the context of chronic inflammation.
Clearly, further research is required to identify the path-
ways and mechanisms through which PSCA is regulated
and deregulated in carcinogenesis.
Conclusion
Our results suggest that PSCA does not play an import-
ant role in the initiation or progression of colorectal car-
cinogenesis. Given that PSCA has been implicated in a
variety of other solid tumours, continued efforts should
be made to elucidate the normal and pathological cellu-
lar functions of PSCA.
Methods
Study population
Between 2008 and 2010, individuals who had tested
positively for faecal occult blood as part of the Scottish
Bowel Cancer Screening Programme, and who had
accepted the invitation of colonoscopic screening, were
invited to participate in a biomarker and colorectal neo-
plasia study (CRANES biomarker study, data not yet
published). Subjects recruited to this study gave a base-
line blood sample that was used for DNA extraction.
Subjects with a previous history of colorectal cancer,
tumour-prone syndromes, or inflammatory bowel disease,
were excluded. DNA samples were available from a total
of 884 subjects who had a complete colonic examination.
Based on colonoscopic findings, these were categorised as
388 samples from subjects with histologically-proven colo-
rectal neoplasia (77 with cancer and 311 with adenomata)
and 496 samples from subjects with no evidence of
neoplasia.
Ethical approval
Ethical approval for the study was granted by the North
of Scotland Regional Ethics Committee. All participants
gave written informed consent.
Genotyping
Genomic DNA samples were genotyped for the rs2294008
polymorphism using a pre-designed TaqManW assay and
the ABI 7900HT Fast Sequence Detection System
(Applied Biosystems, Foster City, CA) as described previ-
ously [15,28]. Genotyping calls were made by two obser-
vers based on the real-time data, resulting in a call rate ofover 99%. Three samples (all controls) failed despite
repeated genotyping attempts.
Statistical analysis
Hardy-Weinberg equilibrium (HWE) of alleles at the
rs2294008 polymorphic locus was assessed using Chi-
squared statistics. Odds ratios (OR) and Cornfield 95%
confidence intervals (CI), adjusted for age and sex, were
computed by logistic regression. All analyses were per-
formed using SPSSW Statistics 19 (IBM, Armonk, NY).
Immunohistochemistry
Four micron sections were cut from archival paraffin
blocks of adenomatous polyps displaying low grade epi-
thelial dysplasia (n= 10), adenomatous polyps with exten-
sive (>50%) high grade epithelial dysplasia (n= 10), and
adenomatous polyps harbouring invasive adenocarcinoma
(n= 10). Immunohistochemical staining for PSCA was
achieved using the EnVisionTM+ system (Dako, Glostrup,
Denmark) as described previously [17,18,29]. Heat-
induced epitope retrieval was performed in Tris/EDTA
buffer, pH 9.0. Sections were incubated for one hour with
an anti-PSCA mouse monoclonal primary antibody
(ab15168, Abcam, Cambridge, UK). Positive staining of
colonic crypt neuroendocrine cells served as an internal
positive control [1].
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